Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial.

Lan-Lan JiangPeng ZhangBing-Li LiuReng-Na YanLei YeJian-Hua Ma Feng-Fei Li

Published in: BioMed research international (2021)

Our data indicate that dapagliflozin adjunct to insulin is a safe and effective therapy for improving glycemic variations, insulin sensitivity, and weight loss in newly diagnosed T2D patients.

Keyphrases

newly diagnosed
type diabetes
glycemic control
weight loss
cardiovascular disease
insulin resistance
minimally invasive
bariatric surgery
clinical trial
ejection fraction
randomized controlled trial
computed tomography
electronic health record
pet imaging
gastric bypass